EU-COVAT-2 BOOSTAVAC
An International Multicentre, Phase 2, Randomised, Adaptive Protocol to determine the safety, optimal timing of and humoral immune response after administering a 3rd homologous mRNA vaccination dose against SARS-CoV-2 in the general population (18+ years) already fully vaccinated against SARS-CoV-2The overarching objective is to evaluate anti-SARS-CoV-2 immune responses to different booster strategies in individuals already vaccinated against SARS-CoV-2. Specifically, this subprotocol will determine the need for, optimal timing of and immunogenicity of administering a 4th homologous vaccination dose against SARS-CoV-2 in the general population (18+ years) who have already been vaccinated with three doses of the BNT162b2 vaccine.
Population: adult | Intervention type: vaccine
